Mimedx (MDXG) Q3 2026 earnings review
Mimedx restores operating profit, but wound sales drop cuts outlook
Mimedx, a maker of surgical and wound healing grafts, returned to operating profit through cost cuts even as its wound business shrank again. Gross margin jumped 11 percentage points from last quarter to 80%, and surgical revenue rose 9% from a year ago. However, wound sales fell 11% from the second quarter, forcing chief executive Joseph Capper to cut the full-year sales outlook.
| Net sales | $62.3M -45% from a year ago (-3% from Q2) |
|---|---|
| Surgical net sales | $40.0M +9% from a year ago (+12% ex one-off by our math) |
| Operating profit (Adjusted EBITDA) | $2.1M -$8.1M last quarter |
| Full-year net sales outlook | Cut $20M new range: $250–260M |
⚖️ Verdict: 🔴 Bearish
The story got worse because the wound stabilization stalled and regulators delayed the Sanara buyout. Three months ago, wound sales were rising from the first quarter and the $350 million acquisition was on track; now wound revenue is falling again, the full-year breakeven profit goal is gone, and an antitrust review has triggered loan commitment fees. On the positive side, April's cost cuts worked as planned, and a $25 million patent settlement plus a court win over the FDA strengthened the standalone business.
The question now is whether hospital wound clinics can grow fast enough to stop the slide in private-office wound sales while Mimedx waits to close the Sanara deal. Optimists point to surgical growth and rising hospital clinic volumes, while sceptics see a shrinking revenue base about to take on $300 million in high-interest debt. Fourth-quarter wound sales and the Federal Trade Commission's review decision will settle the debate.
🐂 Bull Case
Cost Cuts and Factory Gains Restored Operating Profit
Mimedx makes healing grafts from donated human placental tissue and animal collagen. After Medicare capped wound graft prices in January, the company cut staff in April to save $40 million a year. Chief executive Joseph Capper said those savings are now in the run rate and "returned us to positive Adjusted EBITDA", which is operating profit before interest, taxes, depreciation and one-offs.
Profitability improved from last quarter even though total revenue fell 3.2%. Mimedx attributed the rebound to efforts "to remove costs from the business and implement manufacturing efficiencies", alongside a higher mix of surgical products. Selling and administrative costs excluding legal and deal one-offs fell 8.9% from the second quarter to $49.3 million, or 79.2% of sales compared with 84.1% last quarter.
- Gross margin: 79.8%, up 10.8 percentage points from last quarter
- Operating profit (Adjusted EBITDA): $2.1 million, up $10.2 million from last quarter
- GAAP net loss: $8.7 million, narrowed by $6.2 million from last quarter
What to watch: fourth-quarter Adjusted EBITDA margin. A reading near the high-single-digit percentage target set last quarter would confirm the smaller cost base can generate meaningful profit at current sales levels.
Surgical Sales Held Double-Digit Underlying Growth
Mimedx is shifting its business toward operating rooms, where hospitals use its grafts like Amniofix, Amnioeffect and collagen particulate Heliogen to help internal surgical wounds heal. Surgical sales rose 9.1% from a year ago to $40.0 million and now make up 64.2% of total revenue. That comparison was the hardest of the year because surgical sales grew 26.3% in the year-ago quarter.
Capper noted that "While a few discrete items dampened reported Surgical sales growth of 9% in the quarter, underlying demand remained strong across the portfolio" and unit volumes grew in the mid-teens. Last year's third quarter included about $1 million of business-to-business tissue processing that did not repeat. Excluding that one-off item, surgical sales grew 12.2% from a year ago by our math, despite softer US elective surgery volumes.
What to watch: fourth-quarter standalone surgical revenue against last year's $39.4 million. Keeping growth in the low double digits would prove the operating-room franchise can carry the company before the Sanara acquisition closes.
Court Win, Patent Deal and Debt Payoff Bolster Cash
Mimedx scored two legal victories and cleared its bank debt this quarter. A federal court threw out the Food and Drug Administration's ruling that Axiofill, a particulate graft made from human placenta, required a biological drug license, and sent the classification back to the agency. Meanwhile, two 510(k) medical device submissions remain under FDA review to "unlock new markets, applications, coverage and claims".
Separately, a wound care rival settled a patent lawsuit by agreeing to pay Mimedx $25 million over five years, with the first $5 million already received. The medical graft maker also paid off its remaining $17 million term loan, ending September with $120.8 million in cash and zero debt. That leaves a clean balance sheet ahead of the planned Sanara borrowing.
What to watch: the FDA's response to the court remand on Axiofill and its decisions on the two 510(k) device filings. Clearance would give the surgical sales force new approved product claims in 2027.
🐻 Bear Case
Wound Sales Fell From Last Quarter Despite Clinic Volume Gains
Medicare's January 2026 payment rules capped skin-substitute prices at a flat rate per square centimeter and triggered wider payment audits. Capper said "As the Wound Care market works through a sluggish reset, we are beginning to see the anticipated signs of adjustment, including patient migration into Wound Care Centers", where Mimedx's unit volumes rose 7% from the second quarter and over 20% from a year ago.
Yet total wound revenue fell 10.9% from the second quarter to $22.3 million, and dropped 71.0% from a year ago. In the second quarter, Mimedx had pointed to sequential growth as the true measure of recovery when wound sales rose 10.8% from the first quarter. This quarter, the company stopped disclosing total wound volume growth and gave no dollar breakdown by care setting.
- Wound net sales: $22.3 million, down from $25.1 million last quarter
- Wound Care Center unit volume: up 7% from last quarter, down from 44% growth in Q2
- Full-year net sales outlook: cut by $20 million at the middle of the range to $250–260 million
Because departures of mobile and private-office clinics outweighed hospital clinic gains, Mimedx had to cut its full-year sales plan. Furthermore, proposed 2027 Medicare rules keep the flat-rate payment system in place, meaning the lost pricing power will not return.
What to watch: fourth-quarter wound revenue against this quarter's $22.3 million. Another sequential drop would show that private-office losses and price pressure are still outrunning hospital clinic adoption.
Regulators Delayed the Sanara Deal and Triggered Debt Fees
In July, Mimedx agreed to buy Sanara MedTech, a seller of surgical collagen and bone products, for $350 million in cash and stock. Management views the deal as a fast track to make surgical products about three-quarters of combined revenue, while sceptics worry about taking on a $300 million Hayfin loan at the secured overnight rate plus 6.25% while standalone profits are thin.
Sanara shareholders approved the buyout on September 30, but the Federal Trade Commission issued a Second Request for more antitrust information. That review delayed the closing and triggered ticking fees—charges paid to lenders to hold loan funds open—starting in October. Meanwhile, Mimedx softened its first-year combined revenue projection from "well in excess of $400 million" last quarter to "close to $400 million" in its October presentation.
What to watch: FTC clearance timing and the total ticking fees and transaction costs disclosed at closing. A long review adds financing expenses before Mimedx can capture any of the planned $20 million in annual cost savings.
Mimedx Dropped Its Full-Year Profit Target as Legal Costs Rose
For the first half of the year, Mimedx repeatedly forecast that full-year 2026 Adjusted EBITDA would finish "approaching breakeven". With first-half Adjusted EBITDA at negative $19.7 million, hitting that full-year mark required nearly $20 million of positive profit in the second half. Even after returning to positive $2.1 million in the third quarter, nine-month Adjusted EBITDA sits at negative $17.6 million.
In this release, finance chief Doug Rice and Capper dropped the full-year breakeven phrase and said only that fourth-quarter Adjusted EBITDA will rise from the third quarter's $2.1 million. On a GAAP basis, general and administrative expenses reached 30% of revenue ($19 million), up from 13% a year ago, because legal fees and Sanara deal costs jumped to $9.0 million in the quarter.
What to watch: fourth-quarter strategic legal and transaction expenses, which hit $17.6 million over the first nine months. Even after the patent settlement, ongoing lawsuits and the FTC review could keep cash overhead elevated.
💲 Other KPIs
Free cash flow—operating cash flow minus equipment purchases—turned positive at $3.8 million, reversing a $10.6 million cash outflow in the second quarter. However, it remained 87.1% below last year's $29.1 million because of the wound revenue drop. Nine-month free cash flow stands at negative $5.6 million.
Money owed by customers shrank 9.8% from the second quarter's $41.3 million and is down more than half from $75.7 million at year-end. The decline follows lower wound sales and a $5.3 million bad-debt charge in the second quarter. The press release did not disclose this quarter's bad-debt reserve.
The average diluted share count fell 2.6% from 149.7 million a year ago and 1.3% from the second quarter. That reduction reflects the 3.5 million shares Mimedx bought back in the second quarter before halting repurchases to save cash for the Sanara deal, which will issue 4.4 million new shares.
🔮 Guidance
Cut. The surgical and wound graft maker lowered the middle of its full-year sales plan by $20 million, pointing to a 39.1% drop from 2025. By our math, that leaves $69.4 million at the middle of the range for the fourth quarter—up 11.4% from this quarter, but down 41.3% from a year ago. It is the second cut this year after starting at $340–360 million.
Cut. Management expects fourth-quarter operating profit before one-offs to beat the third quarter's $2.1 million, but dropped its earlier statement that full-year 2026 would finish near breakeven. With nine-month Adjusted EBITDA at negative $17.6 million, the full year will stay deeply negative even if the fourth quarter improves.
Unchanged. The company kept its undated long-term goal of low double-digit annual percentage sales growth. Achieving that pace rests on surgical growth and the pending Sanara buyout once the 2026 Medicare wound price reset enters the comparison base next year.
Unchanged. Mimedx repeated its undated long-term goal of an Adjusted EBITDA margin above 20%, compared with 3.3% delivered this quarter. In its investor slides, the company also targets a margin above 20% in the first full year after combining with Sanara, assuming over $20 million in annual cost savings.
❓ Key Questions
Why did total wound revenue fall while hospital clinics grew?
Wound Care Center unit volumes grew 7% from last quarter, yet total wound sales dropped 10.9% to $22.3 million. Investors need the revenue split between private offices and hospital clinics, and whether average prices per unit fell further.
When will the FTCSecond Request on Sanara wrap up?
The antitrust review delayed the Sanara closing and triggered ticking fees on the $300 million Hayfin loan commitment in October. Management has not stated the monthly fee cost, the new target closing date, or when the loan commitment expires.
Did private-office customer bad-debt reserves rise again in Q3?
The allowance for unpaid customer bills jumped to $14.8 million (26.4% of gross receivables) in the second quarter. Because the press release omits the reserve roll-forward, investors must wait for the quarterly 10-Q filing to see if collections stabilised.
How will the $25 million patent settlement be booked?
Mimedx already collected the first $5 million annual payment from its wound care rival. Management did not clarify whether this cash enters fourth-quarter revenue, offsets legal expenses in GAAP operating profit, or gets excluded from Adjusted EBITDA.